US EditionReplimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update
- Replimune Group, Inc. announced financial results for the fiscal second quarter ending September 30, 2025, highlighting a net loss of $83.1 million compared to $53.1 million in the same quarter of 2024.
- The U.S. Food and Drug Administration accepted the BLA resubmission of RP1 for advanced melanoma treatment, with a target action date of April 10, 2026, according to Replimune's announcement.
- Data from the IGNYTE clinical trial shows RP1 combined with nivolumab achieved an overall response rate of 44% in acral melanoma patients, as reported during the ESMO Congress 2025.
- Replimune's cash position decreased to $323.6 million as of September 30, 2025, compared to $483.8 million at fiscal year end March 31, 2025, due to operating activities, mentioned in their financial report.
12 Articles
12 Articles
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Following the NDA submission for icotrokinra treatment of adults and adolescents with moderate to severe plaque psoriasis to the U.S. FDA in July, the European Medicines Agency (EMA) application was submitted in September
Orangeville
Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Encouraging Phase 1 data on ZW191, an antibody-drug conjugate (ADC) targeting folate receptor-⍺ (FR⍺), presented at the AACR-NCI-EORTC ConferenceFirst patient dosed in Phase 1 clinical trial of ZW251 for the treatment of hepatocellular carcinomaAchievement of $25.0 million development milestone from…
Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update
WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal second quarter ended September 30, 2025 and provided…
Coverage Details
Bias Distribution
- 73% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
